gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ALMSHealthcarePharmaceuticals

Alumis Inc. Common Stock (ALMS)

$6.55+0.77%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$6.51▲ 42.76% in range
Nov 3, 2025Low $4.55 · High $30.30Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Alumis closed at $6.55 on Nov 4, up 0.77%, 78.4% below its 52-week closing high. Volume of 1.3M shares was 0.64× its 20-day average (below normal).

Split-adjusted performance: -5.5% over one month, -74.3% over six months, +43.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.66M, down 37.7% from a year earlier, with a net margin of -8557.2%.

Short interest was 11.1M shares at the Oct 15 settlement, up 7.6% from the prior report (11.3% of float, 4.9 days to cover).

Market cap$847.8M129.4M shares
Revenue · quarter$1.7M−37.7% YoY
Diluted EPS$-1.11−244.2% YoY
P/E · TTM—P/S 114.6×
Net margin-8,557.2%Gross 100.0%
Dividend yieldNone
52-week range4.55 – 30.30−78.4% from high
Volume1.3M0.64× 20-day avg
Volatility · 60d180.1%Annualised
Short % of float11.3%4.9 days to cover
Net cash$502.3MCash $502.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −8.1%1M −5.5%3M −76.4%6M −74.3%YTD −32.9%1Y +43.6%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum10
Revenue growth24
Net margin6
Value (low P/E)—
Size68

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short11.1M+7.6% vs prior
Days to cover4.9Settled Oct 15
% of float11.3%
Short vol. 10d32.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ALMSAlumis$6.55+0.77%−74.3%−37.7%−8557.2%—$847.8M
ARDXArdelyx$3.29+8.58%−53.7%+15.7%−0.6%—$849.4MCompare
CYRXCryoPort$16.70+1.52%+31.6%+7.7%−20.9%—$845.8MCompare
AKTSAktis Oncology$15.20+1.74%−24.1%—−713.5%—$845.4MCompare
ANNXAnnexon$4.33+3.34%−24.0%———$820.9MCompare
CRVSCorvus Pharmaceuticals$10.57+7.53%−31.6%———$889.2MCompare
ABUSArbutus Biopharma$4.06+4.64%−8.1%−90.6%−512.0%5.3$804.3MCompare
ANROAlto Neuroscience$23.30+2.64%−4.9%———$914.3MCompare
LTGOLatigo Biotherapeutics$14.04−3.64%————$930.8MCompare

News about Alumis

All news →
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterThe Motley Fool · May 17, 2026▲ PositiveAlumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisGlobeNewswire Inc. · Mar 28, 2026▲ Positive

Quick answers

What does Alumis do?
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
What is ALMS's market cap?
$847.80M, based on the Nov 4 close of $6.55.
Does Alumis pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ALMS is sold short?
11.1M shares, 11.3% of float, as of Oct 15, 2026.
What sector is ALMS in?
Healthcare, in the Pharmaceuticals industry.

About Alumis

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

HQ: South San Francisco, CA239 employeesListed Jun 28, 2024alumis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology